1-(2,3-Dimethylphenyl)-2,2,2-trifluoroethan-1-ol, 98%, 100mg

ETHYL 2-((TERT-BUTOXYCARBONYL)AMINO)-2-(PYRAZIN-2-YL)ACETATE, 95.0%, 250mg

(E)-4-(5-(2-(3-METHYLBENZYLIDENE)HYDRAZINYL)-2-(PYRIDIN-4-YL)PYRAZOLO[1,5-A]PYRIMIDIN-7-YL)MORPHOLINE, 95%, 50mg

6-METHOXY-7-AZAINDOLE-3-CARBOXYLIC ACID, 95.0%, 1g

((4S,5S)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl)bis(diphenylmethanol), 97%, 500g

3-Benzyl-2-bromo-9-methyl-4H,6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,4]oxazepine, 98%, 100mg

2,2-DIMETHYL-1-(MORPHOLIN-4-YL)PROPAN-1-ONE, 95.0%, 500mg

Señales de obligación según ISO 7010, crema protectora de la piel obligatoria, 100 mm, 1 unidad

VERALIPRIDE, 95%, 10mg

6-(3-(Trifluoromethyl)phenyl)picolinic acid, 95%, 5g

rEGCase II assisted by Activator II1vial

(S,Z)-(2-(5-((tert-butyldimethylsilyl)oxy)-2-methylenecyclohexylidene)ethyl)diphenylphosphine oxide, 96%, 250mg

Tetrachlorophthalonitrile>96.0%(GC)(N)5g